vs
MARCUS CORP（MCS）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是MARCUS CORP的1.0倍（$197.9M vs $193.5M），REPLIGEN CORP同比增速更快（13.6% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $17.6M），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 14.4%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
MCS vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.0倍
$193.5M
营收增速更快
RGEN
高出10.9%
2.8%
自由现金流更多
MCS
多$8.8M
$17.6M
两年增速更快
MCS
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $197.9M |
| 净利润 | — | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 0.9% | 9.0% |
| 净利率 | — | 6.7% |
| 营收同比 | 2.8% | 13.6% |
| 净利润同比 | — | 143.9% |
| 每股收益（稀释后） | — | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSRGEN
| Q4 25 | $193.5M | $197.9M | ||
| Q3 25 | $210.2M | $188.8M | ||
| Q2 25 | $206.0M | $182.4M | ||
| Q1 25 | $148.8M | $169.2M | ||
| Q4 24 | $188.3M | $174.1M | ||
| Q3 24 | $232.7M | $154.9M | ||
| Q2 24 | $176.0M | $154.1M | ||
| Q1 24 | $138.5M | $151.3M |
净利润MCSRGEN
| Q4 25 | — | $13.3M | ||
| Q3 25 | $16.2M | $14.9M | ||
| Q2 25 | $7.3M | $14.9M | ||
| Q1 25 | $-16.8M | $5.8M | ||
| Q4 24 | $986.0K | $-30.3M | ||
| Q3 24 | $23.3M | $-654.0K | ||
| Q2 24 | $-20.2M | $3.3M | ||
| Q1 24 | $-11.9M | $2.1M |
毛利率MCSRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率MCSRGEN
| Q4 25 | 0.9% | 9.0% | ||
| Q3 25 | 10.8% | 8.9% | ||
| Q2 25 | 6.3% | 7.6% | ||
| Q1 25 | -13.7% | 3.9% | ||
| Q4 24 | -1.2% | -17.7% | ||
| Q3 24 | 14.1% | -5.1% | ||
| Q2 24 | 1.3% | 1.0% | ||
| Q1 24 | -12.0% | 1.3% |
净利率MCSRGEN
| Q4 25 | — | 6.7% | ||
| Q3 25 | 7.7% | 7.9% | ||
| Q2 25 | 3.6% | 8.2% | ||
| Q1 25 | -11.3% | 3.4% | ||
| Q4 24 | 0.5% | -17.4% | ||
| Q3 24 | 10.0% | -0.4% | ||
| Q2 24 | -11.5% | 2.2% | ||
| Q1 24 | -8.6% | 1.4% |
每股收益（稀释后）MCSRGEN
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | $0.26 | ||
| Q2 25 | — | $0.26 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $-0.55 | ||
| Q3 24 | — | $-0.01 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $767.6M |
| 总债务越低越好 | $159.0M | $542.2M |
| 股东权益账面价值 | $457.4M | $2.1B |
| 总资产 | $1.0B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.35× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资MCSRGEN
| Q4 25 | $23.4M | $767.6M | ||
| Q3 25 | $7.4M | $748.7M | ||
| Q2 25 | $14.9M | $708.9M | ||
| Q1 25 | $11.9M | $697.2M | ||
| Q4 24 | $40.8M | $757.4M | ||
| Q3 24 | $28.4M | $784.0M | ||
| Q2 24 | $32.8M | $809.1M | ||
| Q1 24 | $17.3M | $780.6M |
总债务MCSRGEN
| Q4 25 | $159.0M | $542.2M | ||
| Q3 25 | $162.0M | $537.9M | ||
| Q2 25 | $179.9M | — | ||
| Q1 25 | $198.9M | — | ||
| Q4 24 | $159.1M | $525.6M | ||
| Q3 24 | $173.1M | — | ||
| Q2 24 | $175.7M | — | ||
| Q1 24 | $169.8M | — |
股东权益MCSRGEN
| Q4 25 | $457.4M | $2.1B | ||
| Q3 25 | $454.3M | $2.1B | ||
| Q2 25 | $448.4M | $2.1B | ||
| Q1 25 | $441.8M | $2.0B | ||
| Q4 24 | $464.9M | $2.0B | ||
| Q3 24 | $462.3M | $2.0B | ||
| Q2 24 | $449.4M | $2.0B | ||
| Q1 24 | $459.3M | $2.0B |
总资产MCSRGEN
| Q4 25 | $1.0B | $2.9B | ||
| Q3 25 | $1.0B | $2.9B | ||
| Q2 25 | $1.0B | $2.9B | ||
| Q1 25 | $1.0B | $2.9B | ||
| Q4 24 | $1.0B | $2.8B | ||
| Q3 24 | $1.0B | $2.8B | ||
| Q2 24 | $1.1B | $2.9B | ||
| Q1 24 | $1.0B | $2.8B |
负债/权益比MCSRGEN
| Q4 25 | 0.35× | 0.26× | ||
| Q3 25 | 0.36× | 0.26× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.34× | 0.27× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $17.6M |
| 自由现金流率自由现金流/营收 | 13.6% | 8.9% |
| 资本支出强度资本支出/营收 | 11.6% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $989.0K | $93.9M |
8季度趋势，按日历期对齐
经营现金流MCSRGEN
| Q4 25 | $48.8M | $25.7M | ||
| Q3 25 | $39.1M | $48.1M | ||
| Q2 25 | $31.6M | $28.6M | ||
| Q1 25 | $-35.3M | $15.0M | ||
| Q4 24 | $52.6M | $39.2M | ||
| Q3 24 | $30.5M | $49.3M | ||
| Q2 24 | $36.0M | $42.2M | ||
| Q1 24 | $-15.1M | $44.7M |
自由现金流MCSRGEN
| Q4 25 | $26.4M | $17.6M | ||
| Q3 25 | $18.2M | $43.4M | ||
| Q2 25 | $14.7M | $21.5M | ||
| Q1 25 | $-58.3M | $11.4M | ||
| Q4 24 | $27.1M | $33.6M | ||
| Q3 24 | $12.0M | $42.3M | ||
| Q2 24 | $16.1M | $37.4M | ||
| Q1 24 | $-30.5M | $36.4M |
自由现金流率MCSRGEN
| Q4 25 | 13.6% | 8.9% | ||
| Q3 25 | 8.7% | 23.0% | ||
| Q2 25 | 7.1% | 11.8% | ||
| Q1 25 | -39.2% | 6.8% | ||
| Q4 24 | 14.4% | 19.3% | ||
| Q3 24 | 5.2% | 27.3% | ||
| Q2 24 | 9.2% | 24.3% | ||
| Q1 24 | -22.0% | 24.0% |
资本支出强度MCSRGEN
| Q4 25 | 11.6% | 4.1% | ||
| Q3 25 | 9.9% | 2.5% | ||
| Q2 25 | 8.2% | 3.9% | ||
| Q1 25 | 15.5% | 2.1% | ||
| Q4 24 | 13.5% | 3.2% | ||
| Q3 24 | 7.9% | 4.5% | ||
| Q2 24 | 11.3% | 3.1% | ||
| Q1 24 | 11.1% | 5.5% |
现金转化率MCSRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | 2.41× | 3.23× | ||
| Q2 25 | 4.32× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | 53.31× | — | ||
| Q3 24 | 1.31× | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
RGEN
暂无分部数据
